Evidence map›Paper›PMID 33134567›Full record

RevieweNeurologicalSci2020

Kynurenine pathway in Parkinson's disease-An update.

Dhivya Venkatesan, Mahalaxmi Iyer, Arul Narayanasamy, Kamalakannan Siva, Balachandar Vellingiri

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in eNeurologicalSci, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 2 syntheses or guidelines pooled it, 107 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Monooxygenase Activity of Indoleamine 2,3-Dioxygenase.Journal of the American Chemical Society · 2026
    Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Dhivya VenkatesanHuman Molecular Cytogenetics and Stem Cell Laboratory, Department of Human Genetics and Molecular Biology, Bharathiar University, Coimbatore 641 046, Tamil Nadu, India.
Mahalaxmi IyerDepartment of Zoology, Avinashilingam Institute for Home Science and Higher Education for Women, Coimbatore 641 043, Tamil Nadu, India.
Arul NarayanasamyDisease Proteomics Laboratory, Department of Zoology, Bharathiar University, Coimbatore 641 046, Tamil Nadu, India.
Kamalakannan SivaNational Centre for Disease Control, Ministry of Health and Family Welfare, Government of India, New Delhi 110054, India.
Balachandar VellingiriHuman Molecular Cytogenetics and Stem Cell Laboratory, Department of Human Genetics and Molecular Biology, Bharathiar University, Coimbatore 641 046, Tamil Nadu, India.
Bharathiar University · INAvinashilingam University · INGovernment of India · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is a complex multi-factorial neurodegenerative disorder where various altered metabolic pathways contribute to the progression of the disease. Tryptophan (TRP) is a major precursor in kynurenine pathway (KP) and it has been discussed in various

Indexed as

3-HAA, 3-hydroxyanthranilic acid3-HK, 3-hydroxykynurenine6-OHDA, 6-hydroxydopamineAA, anthranilic acidACMSD, amino-carboxymuconatesemialdehyde decarboxylaseAD, Alzheimer's diseaseAgeingAhR, aryl hydrocarbon receptorATP, adenosine triphosphateBiomarkersCNS, central nervous systemCSF, cerebrospinal fluidDA, dopaminergicFAM, formamidaseIDO-1, indoleamine-2,3-dioxygenasesIFN-γ, interferon-γKATs, kynurenine aminotransferasesKMO, kynurenine −3-monooxygenaseKP, Kynurenine pathwayKYNA, kynurenic acidKYN, kynurenineKynurenine pathway (KP)L-DOPA, L-dopamineLID, L-DOPA-induced dyskinesiaMPTP, 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridineNAD+, nicotinamide adenine dinucleotideNADPH, nicotinamide adenine dinucleotide phosphateNFK, N′-formylkynurenineNMDA, N-methyl-d-aspartatePA, picolinic acidParkinson's disease (PD)PD, Parkinson's diseaseQUIN, quinolinic acidRBCs, red blood cellsSNpc, substantianigra pars compactaTDO, tryptophan 2,3-dioxygenaseTherapeuticsTRP, tryptophanXA, xanthurenic acidZNS, zonisamideα-synuclein, αSyn

Identifiers

PMID33134567
PMCPMC7585940
OpenAlexW3085509898

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.